The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Well, Ole, i hope you are right. I keep holding in the hope of improved trading and eventually profit in 1st generation products. And, of course, as you refer to, the expectation that SweetBiotix will come good. But it is taking forever, due in no small part, to the timescales and priorities of large partners. Firmenich and our mystery US company.
Also, as you point out, there appears to be chunky buying of Opti, which is reassuring. But volumes are not substantial, IMO.
So, I'm convinced that patience is required. And, we could get news next week. But, there again...
Bon vacances à Neuchâtel.
Mol - thanks, as ever. It took me a while to find the article, even though you had taken the time to put the publication in front of my nose.
PS: Healthy aging is a must for Opti holders, if they are to stay around long enough to benefit.
I have a YouTube channel with some pretty ropey covers of all sorts of songs. No charge too:) Needless to say, my advertising revenue is very low. And my profile description includes: "Very little talent, but worse still, no shame." Best wishes to all long-suffering holders. Cheers. MU.
Seems like timing and terminology are key! Let's hope the following statement becomes booked revenue within H2.
"During the first half of the financial year the Group received confirmed orders totalling £1.5m which is 16% greater than turnover for the period to 31 December 2022 of £1.31m. Of the orders received, £552k (2021: £302k) had been completed and invoiced as at 30 June 2023. The increase in sales for the first half of the year reflects strong development in new customer acquisition as well as growth from existing customers. Gross profit for the period amounted to £264k (2022: £154k)."
And as you say reliance is spread over more large partners.